Free Trial
→ Vacuum up cash with these special trades? (From Wealthpin Pro) (Ad)

Relay Therapeutics Q1 2023 Earnings Report

Relay Therapeutics logo
$4.47 -0.03 (-0.67%)
(As of 10:51 AM ET)
Earnings HistoryForecast

Relay Therapeutics Earnings Headlines

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
December 13, 2024 | insidermonkey.com
Jefferies Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)
December 13, 2024 | markets.businessinsider.com
Vacuum up cash with these special trades?
Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.
December 18, 2024 | Wealthpin Pro (Ad)
TD Cowen Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)
December 12, 2024 | markets.businessinsider.com
Relay Therapeutics (RLAY) Gets a Buy from Barclays
December 12, 2024 | markets.businessinsider.com
Relay Therapeutics Reports Promising Data on RLY-2608
December 11, 2024 | markets.businessinsider.com
See More Relay Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email.

About Relay Therapeutics

Relay Therapeutics (NASDAQ:RLAY) operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

View Relay Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles
Upcoming Earnings